Physician profile
Jacob L Moe
NPI 1043574478
$6,663.08
in general payments reported to CMS, 2019-2025
41 companies · $771 in 2025
The $771 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,626 · 2020: $528 · 2021: $597 · 2022: $727 · 2023: $1,304 · 2024: $1,110 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,775.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,039.70 | 2019-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $812.38 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $342.34 | 2019-2022 | |
| Abbvie INC. | $275.19 | 2019-2025 | |
| Dexcom, INC. | $271.19 | 2019-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $219.72 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $176.56 | 2019-2024 | |
| Mannkind Corporation | $157.18 | 2021-2025 | Afrezza |
| Insulet Corporation | $149.42 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.04 | 2019-2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $146.66 | 2023 | |
| Merck Sharp & Dohme LLC | $127.55 | 2019-2021 | |
| Beta Bionics, INC. | $120.44 | 2023 | Ilet Bionic Pancreas |
| Corcept Therapeutics | $107.48 | 2024-2025 | Korlym |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Moe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.